Floatz logo

Belantamab Mafodotin

Plasma Cell Myeloma

GlaxoSmithKlineantibody_drug_conjugatePhase 3Active
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
59/ 100

Competitive context

474 Active assets in the Plasma Cell Myeloma cohort.

Asset / SponsorPhaseRating
Hyaluronidase fihj
Massachusetts General Hospital
Phase 4BBB
Filanesib
PETHEMA Foundation
Phase 2BBB
VINCRISTINE SULFATE
Roswell Park Cancer Institute
Phase 3BBB
CYCLOSPORIN A
Seoul National University Hospital
Phase 3BBB
ANTI-HUMAN T-LYMPHOCYTE IMMUNOGLOBULIN, RABBIT
University of Birmingham
Phase 4BBB

View all 50 →

Same molecule, other indications

Belantamab Mafodotin is also rated in:

hematologic disorderActive
CCC
Indicative · Phase 1/2
48 / 100
View asset →
plasma cell neoplasmActive
CCC
Indicative · Phase 1/2
48 / 100
View asset →
monoclonal gammopathyActive
CC
Indicative · Phase 1/2
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →